Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-1018 vs Shingrix in Healthy Adults >= 50 Years for Herpes Zoster Prevention
NCT06569823Phase 2Active, not recruiting
- Sponsor
- Dynavax Technologies
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Antisense DNA, Small Interfering RNA (siRNA)
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of glycoprotein E + CpG 1018 in herpes zoster (HZ) (11 arms), sponsored by Dynavax Technologies. Primary endpoints: Post-Injection Reactions at 7 days, Adverse Events at 28 days and 3 more. Started Jun 2024; status: active, not recruiting.
02
Drugs
glycoprotein E + CpG 1018
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06569823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569823.